Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid avansor 10 mg kapseli, kova
avansor pharma oy - lenalidomide - kapseli, kova - 10 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid avansor 15 mg kapseli, kova
avansor pharma oy - lenalidomide - kapseli, kova - 15 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid avansor 20 mg kapseli, kova
avansor pharma oy - lenalidomide - kapseli, kova - 20 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid avansor 25 mg kapseli, kova
avansor pharma oy - lenalidomide - kapseli, kova - 25 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid zentiva 15 mg kapseli, kova
zentiva, k.s. - lenalidomide - kapseli, kova - 15 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid zentiva 20 mg kapseli, kova
zentiva, k.s. - lenalidomide - kapseli, kova - 20 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomid zentiva 25 mg kapseli, kova
zentiva, k.s. - lenalidomide - kapseli, kova - 25 mg - lenalidomidi
Европска Унија -
Фински -
EMA (European Medicines Agency)
calquence
astrazeneca ab - acalabrutinib - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomide stada 2.5 mg kapseli, kova
stada arzneimittel ag - lenalidomide - kapseli, kova - 2.5 mg - lenalidomidi
Финска -
Фински -
Fimea (Suomen lääkevirasto)
lenalidomide stada 5 mg kapseli, kova
stada arzneimittel ag - lenalidomide - kapseli, kova - 5 mg - lenalidomidi